Humalog Mix50 (Insulin Lispro)

Humalog Mix50 is indicated for the treatment of diabetes mellitus where both rapid and intermediate insulin coverage are required.

• Type 1 diabetes mellitus in patients requiring mealtime and basal insulin.
• Type 2 diabetes mellitus when oral agents and basal insulin are insufficient.
• Adjunct therapy for patients transitioning from multiple daily injections to a premixed regimen.
• Use in combination with diet and exercise to achieve target glycemic levels.
• May be prescribed for patients who prefer fewer daily injections.
• For adults and pediatric patients (≥6 years) who need a convenient mixed insulin option.

• Insulin lispro binds to the α‑subunit of the insulin receptor on muscle, adipose and hepatic cells, activating the intrinsic tyrosine kinase. This triggers downstream signaling through the PI3K‑Akt pathway, promoting translocation of GLUT‑4 transporters to the cell membrane and increasing glucose uptake. In the liver, receptor activation suppresses gluconeogenesis and glycogenolysis, lowering endogenous glucose production. The rapid onset of action reflects the analogue’s reduced tendency to form hexamers, allowing quicker absorption after subcutaneous injection.

Like other insulin preparations, Humalog Mix50 may be associated with adverse reactions that vary in frequency and severity.

Common

• Hypoglycemia, presenting as sweating, tremor, hunger, or confusion.
• Injection site reactions such as redness, swelling, or itching.
• Lipodystrophy, including lipohypertrophy at repeated injection sites.
• Weight gain associated with improved glycemic control.
• Transient visual disturbances, such as blurred vision, during episodes of low blood sugar.

Serious

• Severe hypoglycemia requiring assistance.
• Allergic reactions ranging from urticaria to anaphylaxis.
• Edema or fluid retention.
• Persistent hyperglycemia indicating possible insulin resistance.

Healthcare professionals should consider several precautions before initiating Humalog Mix50 to ensure safe and effective use.

• Assess renal and hepatic function, as impairment may alter insulin requirements.
• Monitor blood glucose regularly to adjust dose and avoid hypoglycemia.
• Use caution in patients with a history of severe hypoglycemia or hypoglycemia unawareness.
• Evaluate for pregnancy or lactation; insulin may be required but dosing should be individualized.
• Review concomitant medications that affect glucose metabolism.
• Educate patients on proper injection technique and site rotation.
• Consider cardiovascular status, as rapid changes in glucose can affect heart rhythm.

Humalog Mix50 can interact with other agents that influence blood glucose levels or insulin pharmacokinetics.

Avoid

• Concurrent use of other rapid‑acting insulins without dose adjustment.
• Beta‑blockers that may mask hypoglycemia symptoms.
• MAO‑A inhibitors, which can potentiate insulin’s glucose‑lowering effect.
• Glucagon‑like peptide‑1 (GLP‑1) receptor agonists that may require insulin dose reduction.

Use with caution

• Oral antidiabetic drugs (e.g., sulfonylureas, meglitinides) that increase hypoglycemia risk.
• Thiazide diuretics, which may raise blood glucose.
• Corticosteroids, which can cause hyperglycemia and require dose changes.
• Alcohol, especially in excess, as it can unpredictably affect glucose control.
• Exercise, particularly vigorous activity, which can increase insulin sensitivity and precipitate hypoglycemia.